深圳奥礼生物科技

Oli Biotech is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the oral delivery of macromolecular drugs. The company leverages its proprietary SO-Sorb platform to transform injectable biologics, such as peptides and proteins, into convenient oral formulations. Their primary focus areas include metabolic diseases and endocrine disorders, with a pipeline featuring oral versions of GLP-1 receptor agonists and insulin. By overcoming the gastrointestinal barriers to large molecule absorption, Oli Biotech aims to improve patient compliance and therapeutic outcomes. The company has secured significant funding from prominent venture capital firms to advance its lead programs into clinical trials.